IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

Maha H. A.  Hussain

Honoraria - Astellas Pharma; Astellas Pharma; Genentech; MLI PeerView; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Sanofi

Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Pfizer

Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)

Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753

Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer

Thomas  Powles

Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen

Research Funding - AstraZeneca/MedImmune; Roche/Genentech

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech

Peter  Albers

Honoraria - MSD Oncology; Sanofi

Consulting or Advisory Role - MSD Oncology; Roche/Genentech

Daniel  Castellano

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi

Research Funding - Janssen Oncology (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche

Siamak  Daneshmand

Stock and Other Ownership Interests  - Taris

Honoraria - Aduro Biotech; Allergan (I); Bristol-Myers Squibb; Ferring; Janssen; Johnson & Johnson; Nucleix; Olympus; pacific edge; Photocure; QED Therapeutics; Seagen; Spectrum Pharmaceuticals

Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris

Research Funding - Photocure

Travel, Accommodations, Expenses - Photocure

Juergen  Gschwend

Consulting or Advisory Role - Roche

Travel, Accommodations, Expenses - Roche

Hiroyuki  Nishiyama

Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD

Speakers' Bureau - Chugai Pharma; MSD

Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)

Stephane  Oudard

Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi

Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi

Research Funding - Ipsen; Sanofi

Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche

Darren  Tayama

Employment - Roche/Genentech

Stock and Other Ownership Interests  - Roche

Nicole N.  Davarpanah

Employment - Roche/Genentech

Stock and Other Ownership Interests  - Roche

Viraj  Degaonkar

Employment - Genentech/Roche

Stock and Other Ownership Interests  - Genentech/Roche

Travel, Accommodations, Expenses - Genentech/Roche

Yi  Shi

No Relationships to Disclose

Sanjeev  Mariathasan

Employment - Roche/Genentech

Stock and Other Ownership Interests  - Roche

Petros  Grivas

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen

Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)

Peter H.  O'Donnell

Honoraria - Astellas Pharma; Atheneum; Dedham Group; FirstWord; Genentech/Roche; Health Advances; Janssen; Merck; OncLive; Schlesinger Associates; Seagen

Consulting or Advisory Role - Merck

Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - Genentech/Roche; Janssen; Janssen; Merck; Seattle Genetics/Astellas

Other Relationship - Janssen; Nektar; NIH

Jonathan E.  Rosenberg

Stock and Other Ownership Interests  - Illumina

Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico

Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)

Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche

Daniel M.  Geynisman

Employment - 2nd.MD

Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Pfizer; Seattle Genetics/Astellas

Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)

Jean H.  Hoffman-Censits

Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech

Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech

Research Funding - Sanofi

Travel, Accommodations, Expenses - Roche/Genentech

Daniel Peter  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Expert Testimony - Celgene; sanofi

Joaquim  Bellmunt

Stock and Other Ownership Interests  - Rainier Therapeutics

Honoraria - UpToDate

Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre

Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer